Business

Canadian Business Journal, Core One Lab for investigating solicited investments and potential acquisition opportunities

Vancouver, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: How nice), (OTC: CLABF),(Frankfurt: LD6WKN: A3CSSU) (“society” Also “Core One”) Announced that it is actively working to investigate investment and potential acquisition opportunities by strategic psychedelics or pharmaceutical companies, following the recently announced development.

“”Acquisitions or investments by major pharmaceutical companies can be mutually beneficial. As more research is being done on the use of psychedelics to treat depression, addiction, and other psychiatric and cognitive disorders, the market for psychedelic drugs will grow and major pharmaceutical companies will consolidate their industries to become more powerful in the future. Pharmaceutical pipeline,“” Said Joel Shacker, CEO of Core One.

About Core One Labs Inc.

Core One Labs is a life sciences biotechnology R & D company focused on bringing psychedelic medicines to market through the development and manufacture of psychedelic compounds, advances in psychedelic assisted therapies, and the integration of new delivery system technologies.

We take a multi-faceted business approach, incorporating several complementary businesses and units to grow rapidly and establish our position as an industry leader in the emerging psychedelic market.

Through its wholly owned subsidiary, Vocan Biotechnologies Inc., Core One has developed and filed a patent protection for its unique psilocybin production system using artificial bacteria. It also holds four interim patents under Akome Biotech Ltd., a wholly owned subsidiary, for the development of psychedelic-based formulations for neurological and psychiatric disorders, with other wholly owned subsidiaries. He holds three interim patents under one Awakened Biosciences. For additional synthetic techniques for psychedelic and psilocin production methods, Inc.

In addition to developing psychedelics and psychedelic compounds, Core One is interested in four clinics that maintain a combined database of over 275,000 patients. Through the clinic, we will integrate the development of intellectual property related to psychedelic technology and participate in the advancement of psychedelic-based treatment of mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief executive officer

Contact us for more information:
info@core1labs.com
1-866-347-5058

Disclaimer of caution:
The Canadian Stock Exchange has not considered the validity or accuracy of the content of this news release and is not responsible for it.

The information contained in this news release contains forward-looking statements based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. These do not guarantee future performance. We are inherently uncertain about all forward-looking statements, and actual performance may be affected by many important factors, many of which are beyond our control. Please note. Such factors include, among other things, the risks and uncertainties associated with our limited business history and the need to comply with strict regulations. Therefore, actual and future events, situations and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. We undertake no obligation to publicly update or revise any forward-looking information, except as required by applicable securities law.

In addition, psilocybin is now Controlled Drugs and Substances Act (Canada) And owning the substance under it is a criminal offense Controlled Drugs and Substances Act (Canada) No prescription or permission. Health Canada does not approve psilocybin as an indication drug. Core One is not directly or indirectly involved in the illegal sale, manufacture or distribution of psychedelic substances in the jurisdiction in which it operates. Core One believes that psychedelic drugs can be used to treat certain medical conditions, but does not support the legalization of psychedelic drugs for recreational purposes. Core One does not handle psychedelic substances except within the setting of laboratory and clinical trials conducted within the framework of approved regulations.


CBJ News Maker

Canadian Business Journal, Core One Lab for investigating solicited investments and potential acquisition opportunities

Source link Canadian Business Journal, Core One Lab for investigating solicited investments and potential acquisition opportunities

Related Articles

Back to top button